ESMO Reaction
September 15, 2022

ESMO Reactions: ADAURA

ESMO Reaction
September 15, 2022

ESMO Reactions: ADAURA

Author

Osimertinib as adjuvant therapy in patients(pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA

Abstract #LBA47: Masahiro Tsuboi presented two-year follow-up data of disease free survival (DFS) and recurrence patterns from the P3 ADAURA trial, which compared osimertinib(n=339) versus placebo (n=343) in patients with completely resectedEGFRm stage IBꟷIIIA NSCLC ± adjuvant CT.

Results: ContinuedDFS benefit was sustained with osimertinib vs placebo, consistent with the primary analysis. Median DFS was 65.8 mos vs 21.9 mos in osimertinib vs placebo arms, respectively. Fewer pts experienced local/regional and distant recurrence in osimertinib arm vsplacebo (27% vs 60%). Long-term safety profile consistent with known profile of osimertinib.

Oncologist thought leaders cite that DFS remains very impressive for Osimertinib in early EGFRm NSCLC; however, several wonder whether the treatment is more preventative vs. curative

Several commentators are somewhat disappointed to not yet see overall survival (OS) data

A few oncologists mention a particular benefit in reducing CNS relapse

Summary:

Two-year follow-up data from the ADAURA shows impressive disease-free survival benefit with osimertinib in completely resected EGFRm stage IBꟷIIIA NSCLC, particularly with respect to CNS. Based on KM curves, numerous commentators suspect the treatment may have a more preventative vs. curative effect; they seek OS data to clarify this question.

Synthesis by Opus Strategy, LLC.

Download attached file

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.